Mebeverine in irritable bowel syndrome – efficacy and safety of the therapy Review article
Article Sidebar
Published:
Jun 20, 2022
Keywords:
mebeverine, irritable bowel syndrome
Main Article Content
Abstract
Irritable bowel syndrome is a chronic, often recurring, and highly prevalent disorder of gut–brain interaction. In clinical practice, irritable bowel syndrome is characterized by symptoms of recurrent abdominal pain and disordered defecation. Mebeverine hydrochloride is a musculotropic antispasmodic with a direct effect on the smooth muscle of the gastrointestinal tract, relieving spasm without affecting normal gut motility. The article presents current data assessing the efficacy and safety of mebeverine in irritable bowel syndrome based on a systematic literature review published in 2022.
Article Details
How to Cite
Gąsiorowska, A. (2022). Mebeverine in irritable bowel syndrome – efficacy and safety of the therapy. Medycyna Faktow (J EBM), 15(2(55), 205-208. https://doi.org/10.24292/01.MF.0222.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016; 150: 1262-79.
2. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterology Rev. 2018; 13(4): 1-30.
3. Lacy BE, Pimentel M, Brenner DM et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021; 116: 17-44.
4. Vasant DH, Paine PA, Black CJ et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70(7): 1214-40.
5. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B et al. The efficacy of mebeverine in the treatment of irritable bowel syndrome – a systematic review. J Clin Med. 2022; 11: 1044.
6. Guslandi M. Mebeverine plus saccharomyces boulardii versus mebeverine alone in the treatment of irritable bowel syndrome without constipation: A retrospective analysis. Am J Gastroenterol. 2011; 106: S495.
7. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: Results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34: 783-93.
8. Baume P. Mebeverine, an effective agent in the irritable colon syndrome. Aust N Z J Med. 1972; 2: 34-6.
9. Prout BJ. The treatment of irritable bowel syndrome. Two doses of mebeverine compared. Practitioner. 1983; 227: 1607-8.
10. Capurso L, Koch M, Tarquini M et al. The irritable bowel syndrome. A cross-over study of octylonium bromide, mebeverine and placebo. Clin Trials J. 1984; 21: 285-91.
11. Chakraborty DS, Hazra A, Sil A et al. Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? J Fam Med Prim Care. 2019; 8: 3173-8.
12. Schaffstein W, Panijel M, Luettecke K. Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. A multicenter double-blind study. Curr Res Clin Exp. 1990; 47: 136-45.
13. Rahman MZ, Ahmed DS, Mahmuduzzaman M et al. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014; 23: 105-13.
14. Jones RH, Holtmann G, Rodrigo L et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharm. 1999; 13: 1419-27.
15. Sahib AS. Treatment of irritable bowel syndrome using a selected herbal combination of Iraqi folk medicines. J Ethnopharmacol. 2013; 148: 1008-12.
16. Lee KJ, Kim NY, Kwon JK et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine. J Neurogastroenterol Motil. 2011; 23: 1098-104.
17. Hatami K, Kazemi-Motlagh AH, Ajdarkosh H et al. Comparing the Efficacy of Cumin Sofouf With Mebeverine on Irritable Bowel Syndrome Severity and Quality of Life: A Double-blind Randomized Clinical Trial. Crescent J Med Biol Sci. 2020; 7: 186-94.
18. Mokhtare M, Asadipanah M, Bahardoust M et al. Efficacy of adding Luvos® Healing Earth supplementation to mebeverine in improving symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial. Biomed Res. 2018; 5: 2776-83.
19. Tudor GJ. A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome. Br J Clin Pract. 1986; 40: 276-8.
20. Inauen W, Halter F. Clinical Efficacy, Safety and Tolerance of Mebeverine Slow Release (200 mg) vs Mebeverine Tablets in Patients with Irritable Bowel Syndrome. Drug Investig. 1994; 8: 234-40.
21. Van Outryve M, Mayeur S, Meeus MA et al. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm. 1995; 20: 277-82.
22. Gilbody JS, Fletcher CP, Hughes IW et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract. 2000; 54: 461-4.
23. Kruis W, Weinzierl M, Schüssler P et al. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion. 1986; 34: 196-201.
24. Chang FY, Lu CL, Luo JC et al. The evaluation of otilonium bromide treatment in Asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011; 17: 402-10.
25. Lu C, Chen C, Chang F et al. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000; 15: 925-30.
26. Everitt HA, Moss-Morris RE, Sibelli A et al. Management of irritable bowel syndrome in primary care: Feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). BMC Gastroenterol. 2010; 10: 136.
2. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterology Rev. 2018; 13(4): 1-30.
3. Lacy BE, Pimentel M, Brenner DM et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021; 116: 17-44.
4. Vasant DH, Paine PA, Black CJ et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70(7): 1214-40.
5. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B et al. The efficacy of mebeverine in the treatment of irritable bowel syndrome – a systematic review. J Clin Med. 2022; 11: 1044.
6. Guslandi M. Mebeverine plus saccharomyces boulardii versus mebeverine alone in the treatment of irritable bowel syndrome without constipation: A retrospective analysis. Am J Gastroenterol. 2011; 106: S495.
7. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: Results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34: 783-93.
8. Baume P. Mebeverine, an effective agent in the irritable colon syndrome. Aust N Z J Med. 1972; 2: 34-6.
9. Prout BJ. The treatment of irritable bowel syndrome. Two doses of mebeverine compared. Practitioner. 1983; 227: 1607-8.
10. Capurso L, Koch M, Tarquini M et al. The irritable bowel syndrome. A cross-over study of octylonium bromide, mebeverine and placebo. Clin Trials J. 1984; 21: 285-91.
11. Chakraborty DS, Hazra A, Sil A et al. Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? J Fam Med Prim Care. 2019; 8: 3173-8.
12. Schaffstein W, Panijel M, Luettecke K. Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. A multicenter double-blind study. Curr Res Clin Exp. 1990; 47: 136-45.
13. Rahman MZ, Ahmed DS, Mahmuduzzaman M et al. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014; 23: 105-13.
14. Jones RH, Holtmann G, Rodrigo L et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharm. 1999; 13: 1419-27.
15. Sahib AS. Treatment of irritable bowel syndrome using a selected herbal combination of Iraqi folk medicines. J Ethnopharmacol. 2013; 148: 1008-12.
16. Lee KJ, Kim NY, Kwon JK et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine. J Neurogastroenterol Motil. 2011; 23: 1098-104.
17. Hatami K, Kazemi-Motlagh AH, Ajdarkosh H et al. Comparing the Efficacy of Cumin Sofouf With Mebeverine on Irritable Bowel Syndrome Severity and Quality of Life: A Double-blind Randomized Clinical Trial. Crescent J Med Biol Sci. 2020; 7: 186-94.
18. Mokhtare M, Asadipanah M, Bahardoust M et al. Efficacy of adding Luvos® Healing Earth supplementation to mebeverine in improving symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial. Biomed Res. 2018; 5: 2776-83.
19. Tudor GJ. A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome. Br J Clin Pract. 1986; 40: 276-8.
20. Inauen W, Halter F. Clinical Efficacy, Safety and Tolerance of Mebeverine Slow Release (200 mg) vs Mebeverine Tablets in Patients with Irritable Bowel Syndrome. Drug Investig. 1994; 8: 234-40.
21. Van Outryve M, Mayeur S, Meeus MA et al. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm. 1995; 20: 277-82.
22. Gilbody JS, Fletcher CP, Hughes IW et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract. 2000; 54: 461-4.
23. Kruis W, Weinzierl M, Schüssler P et al. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion. 1986; 34: 196-201.
24. Chang FY, Lu CL, Luo JC et al. The evaluation of otilonium bromide treatment in Asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011; 17: 402-10.
25. Lu C, Chen C, Chang F et al. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000; 15: 925-30.
26. Everitt HA, Moss-Morris RE, Sibelli A et al. Management of irritable bowel syndrome in primary care: Feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). BMC Gastroenterol. 2010; 10: 136.